News & Updates
Filter by Specialty:
Conversion to resectability uncommon in trials of unresectable mCRC patients
In clinical trials of patients with unresectable metastatic colorectal cancer (mCRC), conversion to resectability (C2R) rarely happens, reveals a study.
Conversion to resectability uncommon in trials of unresectable mCRC patients
04 Aug 2022
Abiraterone-olaparib confers clinical benefit for mCRPC patients
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
04 Aug 2022
70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients
MammaPrint, a signature test that includes 70 genes, appears to accurately identify hormone receptor-positive breast cancer (HR+BC) patients who are at ultra-low risk of distant recurrence, reports a recent study.
70-gene signature identifies ultra-low risk of distant recurrence in breast cancer patients
04 Aug 2022
Drinking sugar-sweetened beverages detrimental to gut
People who consume sugar-sweetened beverages, rather than artificially sweetened beverages or natural juices, are at increased risk of developing inflammatory bowel disease, especially Crohn’s disease, as reported in a study.
Drinking sugar-sweetened beverages detrimental to gut
04 Aug 2022
Treatment regimen based on small RNAi safe, effective in chronic hepatitis B
In patients with chronic hepatitis B (CHB), treatment with the small interfering RNA JNJ-3989, in combination with a nucleos(t)ide analogue (NA), safely reduces levels of the hepatitis B surface antigen (HBsAg) for up to almost a year after the last dose, a new study has found.